President Donald Trump said Monday he's in no rush to respond to a coordinated attack that hit Saudi Arabia's oil industry over the weekend.Marketsread more
The price of oil could go sharply higher, depending on the duration of the disruption at Saudi oil facilities and whether there is a military response.Powering the Futureread more
Energy stocks, one of the worst-performing sectors this year, spiked Monday after an attack on Saudi Arabia's heart of oil production Saturday sent oil prices soaring.Marketsread more
The Saudi-led military coalition battling Yemen's Houthi movement said on Monday that the attack on Saudi oil plants was carried out by Iranian weapons and did not originate...Oilread more
After a series of setbacks on the road to an initial public offering, the parent company of real estate start-up WeWork is delaying the move, sources told CNBC Monday.Technologyread more
"The United States military, with our interagency team, is working with our partners to address this unprecedented attack and defend the international rules-based order that...Politicsread more
Crude oil's spike following attacks on Saudi Arabia's energy supply has experts weighing whether or not the gains will last.ETF Edgeread more
"In the old days, the averages would've plunged on this kind of oil shock. I know because I've lived through a bunch of them, starting in 1973," Jim Cramer says.Mad Money with Jim Cramerread more
Traders in the fed funds futures market on Monday were pricing in a 34% chance that the Fed will stay put on rates.The Fedread more
The meeting comes amid months of stalled trade talks between Washington and New Delhi, resulting in both sides taking retaliatory measures.Asia Politicsread more
Gas prices could rise by about 20 cents per gallon "starting tomorrow," oil analyst Andy Lipow says Monday.Oil and Gasread more
Generic drug maker maker Mylan on Wednesday reported a first-quarter profit that edged past expectations, helped by demand for products it gained through the acquisition of Swedish drugmaker Meda.
Shares of the EpiPen maker rose 2.3 percent to $38.87 in early trading after Mylan also backed its full-year forecast.
Mylan's forecast for 2017 profit and revenue, which it first announced in March, was in sharp contrast to downbeat expectations from rivals despite prolonged pressure and scrutiny on pricing for generic drugs in the United States.
"Our overall expectations for the global pricing environment are unchanged and we are still predicting mid-single digit percentage erosion globally for the year," Mylan President Rajiv Malik said.
Mylan's affirmation of its 2017 forecast may be comforting to some following the U.S. Food and Drug Administration's (FDA) recent rejection of the company's generic version of GlaxoSmithKline's blockbuster Advair asthma treatment, Goldman Sachs analysts said.
So far, Mylan has provided no details of the FDA's concerns or how long the product might be delayed.
Mylan has come under fire for sharply increasing the price of EpiPen and classifying the life-saving treatment as a generic rather than a branded product, which led to much smaller rebates to state Medicaid programs.
The company said first-quarter sales of EpiPen in North America declined due to increased competition and the launch of its authorized generic.
In March, the company said it was recalling thousands of EpiPen devices following reports of the treatment failing to work in emergencies.
Mylan said net income surged to $66.4 million, or 12 cents per share in the first quarter ended March 31, from $13.9 million, or 3 cents per share, a year earlier.
Excluding one-time items, Mylan earned 93 cents per share, beating analysts' average estimate by 1 cent, according to Thomson Reuters I/B/E/S.
Revenue rose 24 percent to $2.72 billion. Analysts on average had expected $2.84 billion.